Profiling Dynamic Cancer Drug Responses with BioMarker Strategies, LLC and the Bio-Plex® Multiplex Immunoassay System
In an age of personalized medicine, getting the most out of highly targeted cancer therapies takes finding the best molecular targets for each patient. BioMarker Strategies LLC, a small startup, has been developing an innovative method to do this by modeling oncogenic pathway responses, but they needed to accurately measure the levels of phosphoproteins resulting from the activation of these genes. Learn how they are using the Bio-Plex multiplex immunoassay system to accurately quantify the proteins and generate functional signaling profiles for these oncogenes.